AstraZeneca PLC, Nektar Therapeutics (CA) Hedge Bets on Constipation Drug
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Drug giant AstraZeneca plc will submit an experimental oral tablet for constipation to drug regulators next month — moves that could score Nektar Therapeutics Inc. a $95 million payday or allow AstraZeneca to cut its ties to the drug, according to a reworked deal between the companies. The deal, amended from the original 2009 agreement, is full of a series of what-if arrangements that potentially could cut into San Francisco-based Nektar's booty. The drug — called naloxegol, or NKTR-118 — is aimed at relieving constipation caused by pain-killing opioid drugs.
Help employers find you! Check out all the jobs and post your resume.
Drug giant AstraZeneca plc will submit an experimental oral tablet for constipation to drug regulators next month — moves that could score Nektar Therapeutics Inc. a $95 million payday or allow AstraZeneca to cut its ties to the drug, according to a reworked deal between the companies. The deal, amended from the original 2009 agreement, is full of a series of what-if arrangements that potentially could cut into San Francisco-based Nektar's booty. The drug — called naloxegol, or NKTR-118 — is aimed at relieving constipation caused by pain-killing opioid drugs.
Help employers find you! Check out all the jobs and post your resume.